Charles Schwab Investment Management Inc. Acquires 129,416 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Charles Schwab Investment Management Inc. raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 7.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,796,838 shares of the company’s stock after acquiring an additional 129,416 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.82% of Hims & Hers Health worth $43,448,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Yong Rong HK Asset Management Ltd acquired a new position in shares of Hims & Hers Health during the 4th quarter worth about $41,104,000. Principal Financial Group Inc. lifted its holdings in shares of Hims & Hers Health by 370.3% during the 4th quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company’s stock worth $33,024,000 after acquiring an additional 1,075,355 shares during the period. Wellington Management Group LLP lifted its stake in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Hims & Hers Health by 128.7% in the 4th quarter. Bank of New York Mellon Corp now owns 1,244,953 shares of the company’s stock valued at $30,103,000 after purchasing an additional 700,500 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Bank of America reiterated an “underperform” rating and set a $21.00 price objective on shares of Hims & Hers Health in a research report on Thursday, March 6th. Citigroup reissued a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a research report on Thursday, March 6th. TD Cowen reissued a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. BTIG Research started coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Piper Sandler lifted their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $37.23.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $33.10 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98. The firm has a market capitalization of $7.35 billion, a price-to-earnings ratio of 75.24 and a beta of 1.37. The stock’s 50-day simple moving average is $38.49 and its 200-day simple moving average is $28.04.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Andrew Dudum sold 78,127 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $29.62, for a total transaction of $2,314,121.74. Following the completion of the transaction, the chief executive officer now directly owns 109,956 shares in the company, valued at $3,256,896.72. This trade represents a 41.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. The trade was a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 969,191 shares of company stock valued at $34,005,375 in the last three months. 17.71% of the stock is currently owned by insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.